Year |
Citation |
Score |
2024 |
Ogega CO, Skinner NE, Schoenle MV, Wilcox XE, Frumento N, Wright DA, Paul HT, Sinnis-Bourozikas A, Clark KE, Figueroa A, Bjorkman PJ, Ray SC, Flyak AI, Bailey JR. Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance. Immunity. PMID 38518779 DOI: 10.1016/j.immuni.2024.03.001 |
0.409 |
|
2023 |
Frumento N, Sinnis-Bourozikas A, Paul HT, Stavrakis G, Zahid MN, Wang S, Ray SC, Flyak AI, Shaw GM, Cox AL, Bailey JR. Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection. Immunity. PMID 38171362 DOI: 10.1016/j.immuni.2023.12.004 |
0.324 |
|
2022 |
Bozhanova NG, Flyak AI, Brown BP, Ruiz SE, Salas J, Rho S, Bombardi RG, Myers L, Soto C, Bailey JR, Crowe JE, Bjorkman PJ, Meiler J. Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals. Nature Communications. 13: 3178. PMID 35676279 DOI: 10.1038/s41467-022-30865-9 |
0.428 |
|
2022 |
Frumento N, Figueroa A, Wang T, Zahid MN, Wang S, Massaccesi G, Stavrakis G, Crowe JE, Flyak AI, Ji H, Ray SC, Shaw G, Cox AL, Bailey JR. Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency. The Journal of Clinical Investigation. PMID 35588376 DOI: 10.1172/JCI160058 |
0.482 |
|
2022 |
Ogega CO, Skinner NE, Flyak AI, Clark KE, Board NL, Bjorkman PJ, Crowe JE, Cox AL, Ray SC, Bailey JR. B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection. Plos Pathogens. 18: e1010179. PMID 34990486 DOI: 10.1371/journal.ppat.1010179 |
0.407 |
|
2021 |
Weber T, Potthoff J, Bizu S, Labuhn M, Dold L, Schoofs T, Horning M, Ercanoglu MS, Kreer C, Gieselmann L, Vanshylla K, Langhans B, Janicki H, Ströh LJ, Knops E, ... ... Flyak AI, et al. Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. Immunity. PMID 34990590 DOI: 10.1016/j.immuni.2021.12.003 |
0.314 |
|
2021 |
Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Wang Z, C Lorenzi JC, Flyak AI, DeLaitsch AT, Huey-Tubman KE, Hou S, Schiffer CA, Gaebler C, Da Silva J, Poston D, et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. PMID 34331873 DOI: 10.1016/j.immuni.2021.07.008 |
0.607 |
|
2021 |
Murin CD, Gilchuk P, Ilinykh PA, Huang K, Kuzmina N, Shen X, Bruhn JF, Bryan AL, Davidson E, Doranz BJ, Williamson LE, Copps J, Alkutkar T, Flyak AI, Bukreyev A, et al. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. Cell Reports. 35: 108984. PMID 33852862 DOI: 10.1016/j.celrep.2021.108984 |
0.766 |
|
2021 |
Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Lorenzi JCC, Flyak AI, DeLaitsch AT, Huey-Tubman KE, Hou S, Schiffer CA, Gaebler C, Wang Z, Da Silva J, Poston D, et al. Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. Biorxiv : the Preprint Server For Biology. PMID 33758864 DOI: 10.1101/2021.03.07.434227 |
0.586 |
|
2020 |
Flyak AI, Ruiz SE, Salas J, Rho S, Bailey JR, Bjorkman PJ. Author response: An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein Elife. DOI: 10.7554/Elife.53169.Sa2 |
0.44 |
|
2019 |
Kinchen VJ, Massaccesi G, Flyak AI, Mankowski MC, Colbert MD, Osburn WO, Ray SC, Cox AL, Crowe JE, Bailey JR. Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. The Journal of Clinical Investigation. 130. PMID 31408439 DOI: 10.1172/Jci130720 |
0.349 |
|
2019 |
Colbert MD, Flyak AI, Ogega CO, Kinchen VJ, Massaccesi G, Hernandez M, Davidson E, Doranz BJ, Cox AL, Crowe JE, Bailey JR. Broadly neutralizing antibodies targeting new sites of vulnerability in hepatitis C virus E1E2. Journal of Virology. PMID 31068427 DOI: 10.1128/Jvi.02070-18 |
0.425 |
|
2019 |
King LB, West BR, Moyer CL, Gilchuk P, Flyak A, Ilinykh PA, Bombardi R, Hui S, Huang K, Bukreyev A, Crowe JE, Saphire EO. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk. Nature Communications. 10: 1788. PMID 30996276 DOI: 10.1038/S41467-019-09732-7 |
0.709 |
|
2019 |
Williamson L, Flyak AI, Kose N, Bombardi R, Branchizio A, Reddy S, Davidson E, Doranz B, Fusco ML, Saphire EO, Halfmann PJ, Kawaoka Y, Piper AE, Glass PJ, Crowe JE. Early human B cell response to Ebola virus in four U.S. survivors of infection. Journal of Virology. PMID 30728263 DOI: 10.1128/Jvi.01439-18 |
0.766 |
|
2018 |
Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE, Bailey JR, Bjorkman PJ. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Cell Host & Microbe. 24: 703-716.e3. PMID 30439340 DOI: 10.1016/J.Chom.2018.10.009 |
0.348 |
|
2018 |
Ilinykh PA, Santos RI, Gunn BM, Kuzmina NA, Shen X, Huang K, Gilchuk P, Flyak AI, Younan P, Alter G, Crowe JE, Bukreyev A. Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap. Plos Pathogens. 14: e1007204. PMID 30138408 DOI: 10.1371/Journal.Ppat.1007204 |
0.639 |
|
2018 |
Kuzmina NA, Younan P, Gilchuk P, Santos RI, Flyak AI, Ilinykh PA, Huang K, Lubaki NM, Ramanathan P, Crowe JE, Bukreyev A. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors. Cell Reports. 24: 1802-1815.e5. PMID 30110637 DOI: 10.1016/J.Celrep.2018.07.035 |
0.59 |
|
2018 |
Gilchuk P, Kuzmina N, Ilinykh PA, Huang K, Gunn BM, Bryan A, Davidson E, Doranz BJ, Turner HL, Fusco ML, Bramble MS, Hoff NA, Binshtein E, Kose N, Flyak AI, et al. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity. PMID 30029854 DOI: 10.1016/J.Immuni.2018.06.018 |
0.793 |
|
2018 |
Gilchuk P, Mire CE, Geisbert JB, Agans KN, Deer DJ, Cross RW, Slaughter JC, Flyak AI, Mani J, Pauly MH, Velasco J, Whaley KJ, Zeitlin L, Geisbert TW, Crowe JE. Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. The Journal of Infectious Diseases. PMID 29982718 DOI: 10.1093/Infdis/Jiy295 |
0.593 |
|
2018 |
Flyak AI, Kuzmina N, Murin CD, Bryan C, Davidson E, Gilchuk P, Gulka CP, Ilinykh PA, Shen X, Huang K, Ramanathan P, Turner H, Fusco ML, Lampley R, Kose N, et al. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. Nature Microbiology. PMID 29736037 DOI: 10.1038/S41564-018-0157-Z |
0.792 |
|
2018 |
King LB, Fusco ML, Flyak AI, Ilinykh PA, Huang K, Gunn B, Kirchdoerfer RN, Hastie KM, Sangha AK, Meiler J, Alter G, Bukreyev A, Crowe JE, Saphire EO. The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. Cell Host & Microbe. 23: 101-109.e4. PMID 29324225 DOI: 10.1016/J.Chom.2017.12.003 |
0.748 |
|
2017 |
Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE, Bailey JR. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proceedings of the National Academy of Sciences of the United States of America. PMID 29255018 DOI: 10.1073/Pnas.1718441115 |
0.331 |
|
2017 |
Bailey JR, Flyak AI, Cohen VJ, Li H, Wasilewski LN, Snider AE, Wang S, Learn GH, Kose N, Loerinc L, Lampley R, Cox AL, Pfaff JM, Doranz BJ, Shaw GM, et al. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. Jci Insight. 2. PMID 28469084 DOI: 10.1172/Jci.Insight.92872 |
0.345 |
|
2017 |
Mire CE, Geisbert JB, Borisevich V, Fenton KA, Agans KN, Flyak AI, Deer DJ, Steinkellner H, Bohorov O, Bohorova N, Goodman C, Hiatt A, Kim DH, Pauly MH, Velasco J, et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Science Translational Medicine. 9. PMID 28381540 DOI: 10.1126/Scitranslmed.Aai8711 |
0.607 |
|
2016 |
Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, et al. A "Trojan horse" bispecific antibody strategy for broad protection against ebolaviruses. Science (New York, N.Y.). PMID 27608667 DOI: 10.1126/Science.Aag3267 |
0.647 |
|
2016 |
Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, Zeitlin L, Crowe JE, Andersen KG, Saphire EO, Ward AB. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nature Microbiology. 1: 16128. PMID 27562261 DOI: 10.1038/Nmicrobiol.2016.128 |
0.574 |
|
2016 |
Ilinykh PA, Shen X, Flyak AI, Kuzmina N, Ksiazek TG, Crowe JE, Bukreyev A. Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies. Journal of Virology. PMID 26819310 DOI: 10.1128/Jvi.00101-16 |
0.641 |
|
2016 |
Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, et al. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Cell. PMID 26806128 DOI: 10.1016/J.Cell.2015.12.022 |
0.803 |
|
2015 |
Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak AI, Crowe JE, Chandran K, Saphire EO. Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies. Mbio. 7. PMID 26908579 DOI: 10.1128/Mbio.02154-15 |
0.542 |
|
2015 |
Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomadiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, et al. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Cell Host & Microbe. 18: 86-95. PMID 26159721 DOI: 10.1016/J.Chom.2015.06.009 |
0.752 |
|
2015 |
Hashiguchi T, Fusco ML, Bornholdt ZA, Lee JE, Flyak AI, Matsuoka R, Kohda D, Yanagi Y, Hammel M, Crowe JE, Saphire EO. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell. 160: 904-12. PMID 25723165 DOI: 10.1016/J.Cell.2015.01.041 |
0.68 |
|
2015 |
Flyak AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdt ZA, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Ward AB, Saphire EO, Bukreyev A, et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell. 160: 893-903. PMID 25723164 DOI: 10.1016/J.Cell.2015.01.031 |
0.779 |
|
2015 |
Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, et al. Erratum: Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus (Cell Host and Microbe (2015) 18 (86-95)) Cell Host & Microbe. 18. DOI: 10.1016/J.Chom.2015.08.002 |
0.761 |
|
2011 |
Nikolaiev YS, Gilchuk PV, Gorbatiuk OB, Flyak AI, Labyntsev AJ, Irodov DM, Kolibo DV, Kordium VA. Polyclonal antibodies against the human cell surface CD34 marker Cytology and Genetics. 45: 133-142. DOI: 10.3103/S0095452711030066 |
0.369 |
|
2009 |
Flyak AI, Pavlova MV, Gilchuk PV. In silico analysis of the structure of variable domains of mouse single-chain antibodies specific to the human recombinant interferon β1b Cytology and Genetics. 43: 42-47. DOI: 10.3103/S0095452709010083 |
0.454 |
|
Show low-probability matches. |